The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Efficacy of Agomelatine in Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled Study
Abstract
BACKGROUND: Agomelatine is a novel agent that acts on melatonergic (MT(1), MT(2)) receptors and serotonergic (5-HT(2C)) receptors. Preclinical data and data from clinical trials in major depression suggest that agomelatine may have anxiolytic properties. A randomized, double-blind, placebo-controlled trial was designed to assess the efficacy of agomelatine in generalized anxiety disorder (GAD). METHODS: One hundred twenty-one patients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition GAD and no comorbid disorders were randomized to agomelatine (25-50 mg/d) or placebo for 12 weeks. The primary outcome measure was the Hamilton Anxiety Rating Scale, whereas secondary outcome measures included the Clinical Global Impression scales, the Leeds Sleep Evaluation Questionnaire, and the Sheehan Disability Scale. Safety measures included assessment of spontaneously reported adverse events, laboratory monitoring, and the Discontinuation Emergent Signs and Symptoms Scale to evaluate discontinuation symptoms. RESULTS: Analysis of covariance of change in the last Hamilton Anxiety Rating Scale total score from baseline demonstrated significant superiority of agomelatine 25 to 50 mg as compared with placebo (E [SE] = -3.28 [1.58]; 95% confidence interval = -6.41 to -0.15; P = 0.040). Data on secondary outcome measures, including clinical response, symptoms of insomnia, and improvement in associated disability, were consistent with the efficacy of agomelatine. Safety analysis indicated that agomelatine was tolerated as well as placebo and was devoid of discontinuation emergent symptoms. CONCLUSIONS: This study suggests that agomelatine is effective in the treatment of GAD and is well tolerated. Additional trials, using an active comparator and extending over a longer period, are needed to delineate the place of agomelatine in the contemporary pharmacotherapy for anxiety disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Sheehan, D. V., Harnett-Sheehan, K., & Raj, B. A. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199606003-00015 · Cited by 1,440
Research works printed but not linked: 22
- Millan, 2003, The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways., J Pharmacol Exp Ther, 306, 954, 10.1124/jpet.103.051797 · DOI · Paper page
- Millan, 2005, Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade., Psychopharmacologia, 177, 448, 10.1007/s00213-004-1962-z · DOI · Paper page
- Loiseau, 2006, Effects of melatonin and agomelatine in anxiety-related procedures in rats: interaction with diazepam., Eur Neuropsychopharmacol, 16, 417, 10.1016/j.euroneuro.2005.11.007 · DOI
- Papp, 2006, Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety., Behav Pharmacol, 17, 9
- Loo, 2002, Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study., Int Clin Psychopharmacol, 17, 239, 10.1097/00004850-200209000-00004 · DOI · Paper page
- Kennedy, 2006, Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. European neuropsychopharmacology., Eur Neuropsychopharmacol, 16, 93, 10.1016/j.euroneuro.2005.09.002 · DOI · Paper page
- Olie, 2007, Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder., Int J Neuropsychopharmacol, 4, 1
- Den Boer, 2006, Clinical efficacy of agomelatine in depression: the evidence., Int Clin Psychopharmacol, 21, S21, 10.1097/01.yic.0000195661.37267.86 · DOI
- Dubocovich, 2006, Agomelatine targets a range of major depressive disorder symptoms., Curr Opin Investig Drugs, 7, 670
- Ballenger, 2001, Consensus statement on generalized anxiety disorder from the international consensus group on depression and anxiety., J Clin Psychiatry, 62, 53
- Bandelow, 2002, WFSBP task force on treatment guidelines for anxiety, obsessive-compulsive and posttraumatic stress disorders. World federation of societies of biological psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders., World J Biol Psychiatry, 3, 171, 10.3109/15622970209150621 · DOI · Paper page
- Allgulander, 2003, WCA recommendations for the long-term treatment of generalized anxiety disorder., CNS Spectr, 8, 53, 10.1017/S1092852900006945 · DOI
- Baldwin, 2005, Evidence-based pharmacotherapy of Generalized Anxiety Disorder., Int Clin Psychopharmacol, 8, 293
- Montgomery, 2004, Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study., Int Clin Psychopharmacol, 19, 271, 10.1097/01.yic.0000137184.64610.c8 · DOI · Paper page
- Kessler, 2000, The epidemiology of pure and comorbid generalized anxiety disorder. A review and evaluation of recent research., Acta Psychiatr Scand, 406, 7, 10.1111/j.0065-1591.2000.acp29-02.x · DOI
- Stein, 2001, Comorbidity in generalized anxiety disorder: impact and implications., J Clin Psychiatry, 62, 29
- Sheehan, 1998, The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10., J Clin Psychiatry, 59, 22
- Hamilton, 1959, A rating scale for anxiety., J Neurol Neurosurg Psychiatr, 23, 56, 10.1136/jnnp.23.1.56 · DOI · Paper page
- Zigmond, 1983, The Hospital Anxiety and Depression Scale., Acta Psychiatr Scand, 67, 361, 10.1111/j.1600-0447.1983.tb09716.x · DOI · Paper page
- Stein, 2005, Generalized anxiety disorder: rethinking diagnosis and rating., CNS Spectr, 10, 930, 10.1017/S1092852900010488 · DOI
- Parrott, 1980, The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations - a review., Psychopharmacologia, 71, 173, 10.1007/BF00434408 · DOI · Paper page
- Rosenbaum, 1998, Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial., Biological Psychiatry, 44, 77, 10.1016/S0006-3223(98)00126-7 · DOI · Paper page
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Sertraline [556,559-561] 1 Agomelatine [584,585] 1”
Treatment of anxiety disorders
Bandelow, B., Michaelis, S., & Wedekind, D. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.2/bbandelow · Cited by 811
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development
de Bodinat, C., Guardiola-Lemaitre, B., Mocaër, E., Renard, P., Muñoz, C., & Millan, M. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3140 · Cited by 593
Self-citationSleep and anxiety: From mechanisms to interventions
Chellappa, S. L., & Aeschbach, D. (2022) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2021.101583 · Cited by 509
Metadata
- Authors
- Stein, D. J., Ahokas, A. A., & de Bodinat, C.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2008-10
- Volume
- 28
- Issue
- 5
- Pages
- 561-566
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W1967246300
- Cited by
- 174
- References
- 2
- FWCI
- 20.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of Agomelatine in Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled Study. https://app.cochat.ai/papers/10.1097/jcp.0b013e318184ff5b
- The paper
- Stein, D. J., Ahokas, A. A., & de Bodinat, C. (2008). Efficacy of Agomelatine in Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled Study. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e318184ff5b
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.